佰金生命科学因转换可换股债券发行1.199亿股

Core Viewpoint - The company, Baijin Life Sciences (01466), has received a conversion notice from bondholders regarding the exercise of convertible bonds, leading to the issuance of new shares [1] Group 1: Convertible Bonds and Share Issuance - On September 29, 2025, the company received a notice from bondholders to convert HKD 31.5 million of convertible bonds at a conversion price of HKD 0.2628 per share [1] - A total of 119.9 million shares will be issued, representing approximately 15.52% of the company's existing issued share capital and about 13.43% of the enlarged issued share capital post-conversion [1] - The new shares are scheduled to be allotted and issued to the bondholders on October 8, 2025 [1]